Labcorp offers nationwide test to identify ovarian cancer patients eligible for Merck's KEYTRUDA treatment.

Labcorp has launched nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx test, the only FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer eligible for Merck's KEYTRUDA and KEYTRUDA QLEX treatments. These treatments are the first FDA-approved PD-1 inhibitors for this cancer type, offering new hope by improving progression-free and overall survival. Labcorp's rapid testing access supports clinicians in quickly identifying patients who may benefit from these therapies, addressing a critical need as platinum-resistant ovarian cancer has limited treatment options and poor outcomes.